ABSTRACT
Background An estimated 40% of people who developed tuberculosis in 2021 were not diagnosed or treated. Pre-chemotherapy era data are a rich resource on survival for people with untreated TB. We aimed to identify heterogeneities in these data to inform more precise use of them.
Methods We extracted survival data from pre-chemotherapy era papers reporting TB specific mortality and/or natural recovery data. We used Bayesian parametric survival analysis to model the survival distribution, stratifying by geography (North America versus Europe), time (pre-1930 versus post-1930), and setting (sanitoria versus non-sanitoria).
Results We found 12 studies with TB-specific mortality data. Ten-year survival was 69% in North America (95 CI: 54%-81%) and 36% in Europe (95% CI: 10%-71%). Only 38% (95% CI: 18%-63%) of non-sanitorium individuals survived to 10 years compared to 69% (95% CI: 41%-87%) of sanitoria/hospitalized patients. There were no significant differences between people diagnosed pre-1930 and post-1930 (five-year survival pre-1930: 65%; 95% CI: 44%-88% versus post-1930: 72%; 95% CI: 41%-94%).
Conclusions Mortality and natural recovery risks vary substantially by location and setting. These heterogeneities need to be considered when using pre-chemotherapy data to make inferences about expected survival of people with undiagnosed TB.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The results reported herein correspond to specific aims of grants R01GM122876 and R35GM141821 to investigator LFW, HEJ, and CRH, and R01GM122876-04S1 to CAR from the National Institute of General Medical Sciences of the National Institutes of Health. This work was also supported by grant K23 AI152930 from the National Institutes of Health to TCB and a Burroughs Wellcome Fund/American Society for Tropical Medicine and Hygiene Postdoctoral Fellowship in Tropical Infectious Diseases to TCB. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data and code are available on GitHub at https://github.com/sarahleavitt/TB_mortality.
